Topics

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

2016-11-15 11:38:21 | BioPortfolio

Summary

Prospective national multicenter open label phase II Remodel WM3 trial

Description

An Open Label non-randomized Phase II Study exploring chemo-free treatment association with Idelalisib and Obinutuzumab in Patient with relapsed refractory Waldenstrom's Macroglobulinemia

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Waldenstrom Macroglobulinemia

Intervention

Obinutuzumab, Idelalisib

Status

Not yet recruiting

Source

French Innovative Leukemia Organisation

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-11-15T11:38:21-0500

Clinical Trials [186 Associated Clinical Trials listed on BioPortfolio]

A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1

This is a multi-center, single-arm, open label, non-randomized, phase II study designed to investigate the efficacy, safety and tolerability of obinutuzumab given as monotherapy in patient...

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

The purpose of this research study is to assess the response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. LBH589 is a newly discovered compound ...

Study of VTD in Waldenstrom's Macroglobulinemia

This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients with ne...

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

The purpose of this study is to evaluate the efficacy of ibrutinib based on overall response rate (ORR) (partial response [PR] or better) by investigator assessment per the modified Consen...

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).

PubMed Articles [23 Associated PubMed Articles listed on BioPortfolio]

Bilateral vision loss in Waldenstrom's macroglobulinemia.

Waldenström macroglobulinemia. Experience in 31 patients.

Waldenström macroglobulinemia (WM) is an uncommon indolent B-cell lymphoma, due to the proliferation of lymphoplasmacytic cells, and secretion of a monoclonal IgM protein.

PKPD assessment of the anti-CD20 antibody obinutuzumab in cynomolgus monkey is feasible despite marked anti-drug antibody response in this species.

The pharmacokinetics (PK) of the anti-CD20 monoclonal antibody obinutuzumab was assessed following single intravenous dosing to cynomolgus monkeys. In addition, the pharmacokinetic-pharmacodynamic (PK...

Imaging of Waldenström Macroglobulinemia: A Comprehensive Review for the Radiologist in the Era of Personalized Medicine.

We describe the range of organ systems involved and the spectrum of imaging findings seen in Waldenström macroglobulinemia (WM). Although imaging is not mandatory in the initial workup of a patient ...

Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.

Follicular lymphoma is the most common subtype of the indolent non-Hodgkin lymphomas. Treatment usually consists of immuno-chemotherapy and results in long-lasting remissions in most cases. Progressio...

Medical and Biotech [MESH] Definitions

A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.

More From BioPortfolio on "Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Searches Linking to this Trial